World Journal of
Pharmaceutical and Life Sciences

THE STUDY OF VARIOUS CANCER CELL LINES: CLINICAL EVALUATION METHODS

Suvarna Deshmukh*, Sourabh Patil, Shreyash Koli, Dipali Patil, Sachin Navale, Mr. Pritam Salokhe and Dr. Nilesh Chougule

ABSTRACT

More than 277 distinct forms of cancer disease are referred to as cancer in the broadest sense. Several cancer stages have been identified by researchers, indicating that a variety of gene changes may contribute to the development of cancer. Often, cell lines are employed instead of real cells to research biological processes. A cautious approach must be taken in assessing the outcomes, as cell lines might not accurately reproduce the original cells. Several cancer cell lines, such as MCF-7, HeLa, A549, HCT-116, PC-3, U-87 MG, HepG2, and K562 cells, will be briefly discussed in this article. Clinical trials that are meant to be approved by regulators must show the drug's therapeutic effects in a specific population. A drug's clinical development is carried out in stages through a series of clinical studies. Following the evaluation of safety and pharmacokinetics, as well as the recommendation of dosage and mode of oversight, an exploratory assessment of efficacy and safety is conducted. Three stages have usually been engaged in clinical development: phase I, II, and III studies. It has been carried out in a progressive manner. The procedure of clinically evaluating anticancer drugs and the most often utilised cancer cell lines are briefly summarised in this article.

[Full Text Article]   [Download Certificate]